These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18705236)

  • 1. Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
    Franchini M; Mannucci PM
    Blood Transfus; 2008 Jul; 6(3):127-35. PubMed ID: 18705236
    [No Abstract]   [Full Text] [Related]  

  • 2. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S; Fujimura Y
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADAMTS-13 assays in thrombotic thrombocytopenic purpura.
    Peyvandi F; Palla R; Lotta LA; Mackie I; Scully MA; Machin SJ
    J Thromb Haemost; 2010 Apr; 8(4):631-40. PubMed ID: 20088924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Congenital ADAMTS13 deficiency: a rare mimicker of immune thrombocytopenic purpura.
    Quintero V; Garcia-Pose A; Barrios-Tascon A; Pacheco-Cumani M
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):653-5. PubMed ID: 24942015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic thrombocytopenic purpura: a moving target.
    Sadler JE
    Hematology Am Soc Hematol Educ Program; 2006; ():415-20. PubMed ID: 17124092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic thrombocytopenic purpura and its diagnosis.
    Veyradier A; Meyer D
    J Thromb Haemost; 2005 Nov; 3(11):2420-7. PubMed ID: 15892859
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.
    Tsai HM
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):609-32, v. PubMed ID: 17666281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.
    Grillberger R; Casina VC; Turecek PL; Zheng XL; Rottensteiner H; Scheiflinger F
    Haematologica; 2014 Apr; 99(4):e58-60. PubMed ID: 24532042
    [No Abstract]   [Full Text] [Related]  

  • 9. Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura.
    Mannucci PM; Franchini M
    Presse Med; 2012 Mar; 41(3 Pt 2):e157-62. PubMed ID: 22244722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Current perspectives on EHEC, complement mutations and ADAMTS13].
    Karpman D
    Lakartidningen; 2008 Apr 9-15; 105(15):1096-101. PubMed ID: 18561752
    [No Abstract]   [Full Text] [Related]  

  • 11. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.
    Li D; Xiao J; Paessler M; Zheng XL
    Thromb Haemost; 2011 Nov; 106(5):947-58. PubMed ID: 21901237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.
    Sato A; Hoshi Y; Onuma M; Sato R; Tsunematsu Y; Isonishi A; Matsumoto M; Fujimura Y; Imaizumi M
    Pediatr Hematol Oncol; 2010 Feb; 27(1):53-8. PubMed ID: 20121555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombotic thrombocytopenic purpura and its imitators.
    Braverman AS
    South Med J; 2009 May; 102(5):455-6. PubMed ID: 19373136
    [No Abstract]   [Full Text] [Related]  

  • 15. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
    Shortt J; Oh DH; Opat SS
    N Engl J Med; 2013 Jan; 368(1):90-2. PubMed ID: 23281998
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C.
    Kitano K; Gibo Y; Kamijo A; Furuta K; Oguchi S; Joshita S; Takahashi Y; Ishida F; Matsumoto M; Uemura M; Fujimura Y
    Haematologica; 2006 Aug; 91(8 Suppl):ECR34. PubMed ID: 16923518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ADAMTS13--actor and marker in thrombotic microangiopathy].
    Gøtze JP; Lindblom A; Björk P; Nielsen LB; Strandberg K; Manea M; Hillarp A
    Lakartidningen; 2008 Apr 9-15; 105(15):1092-5. PubMed ID: 18561751
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.
    Zheng XL; Wu HM; Shang D; Falls E; Skipwith CG; Cataland SR; Bennett CL; Kwaan HC
    Haematologica; 2010 Sep; 95(9):1555-62. PubMed ID: 20378566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
    Starke R; Machin S; Scully M; Purdy G; Mackie I
    Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency.
    George JN; Chen Q; Deford CC; Al-Nouri Z
    J Clin Apher; 2012; 27(6):302-11. PubMed ID: 22927184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.